市場調查報告書

先天性水皰症(EB)- 流行病學預測 2028年

Epidermolysis Bullosa (EB) - Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 918183
出版日期 內容資訊 英文 81 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
先天性水皰症(EB)- 流行病學預測 2028年 Epidermolysis Bullosa (EB) - Epidemiology Forecast - 2028
出版日期: 2019年12月01日內容資訊: 英文 81 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的先天性水皰症(EB)的2017年的患病數估算為3萬9,433人。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的先天性水皰症(EB)市場相關調查,疾病概要,流行病學的預測,患病數的變化與預測等資料彙整。

目錄

第1章 重要洞察

第2章 先天性水皰症(EB)市場概要

  • 先天性水皰症(EB)的分佈(實在數值)
  • 先天性水皰症(EB)的分佈(預測值)

第3章 疾病概要:先天性水皰症(EB)

  • 簡介
  • 原因
  • 症狀
  • 分類
  • 病理生理學
  • 遺傳性基礎
  • 診斷
  • 診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的先天性水皰症(EB)的總患病數
  • 主要7個國家的先天性水皰症(EB)的診斷患病數
  • 主要7個國家的先天性水皰症(EB)的診斷患病數:各類型

第5章 先天性水皰症(EB)的流行病學預測:各國

  • 美國
    • 先天性水皰症(EB)的總患病數
    • 先天性水皰症(EB)的診斷患病數
    • 先天性水皰症(EB)的診斷患病數:各類型
  • 歐盟5國
    • 德國
      • 先天性水皰症(EB)的總患病數
      • 先天性水皰症(EB)的診斷患病數
      • 先天性水皰症(EB)的診斷患病數:各類型
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本
    • 先天性水皰症(EB)的總患病數
    • 先天性水皰症(EB)的診斷患病數
    • 先天性水皰症(EB)的診斷患病數:各類型

第6章 附錄

第7章 DelveInsight的服務內容

第8章 免責聲明

第9章 關於DelveInsight

目錄
Product Code: DIEI0399

DelveInsight's 'Epidermolysis Bullosa (EB)-Epidemiology Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology trends of EB in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes, which form the intraepidermal adhesion and dermo-epidermal anchoring complex within the basement membrane zone (BMZ) of the skin and mucosae. Epidermolysis bullosa usually is diagnosed in babies and children, but milder types can develop later in adulthood.

EB may be inherited in either a dominant or recessive form. In dominant EB, one parent usually carries the gene and is affected by the condition themselves, while the birth of a child suffering from the recessive form is usually totally unexpected since both parents can carry the EB gene without displaying the condition themselves. In dominant EB, there is a 50% chance of passing the disorder to children: in recessive EB the chance is 25%.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Epidermolysis Bullosa (EB)-Disease Understanding

Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma.

There are four major types of EB, depending on the location of the target proteins and level of the blisters: EB simplex (epidermolytic), junctional EB (lucidolytic), dystrophic EB (dermolytic), and Kindler syndrome (mixed levels of blistering). Apart from this when EB also occurs due to any defect in the immune system it is called epidermolysis bullosa acquisita (EBA).

Epidermolysis Bullosa (EB) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalent Cases of Epidermolysis Bullosa (EB) in the 7MM, Total Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in the 7MM, and Type-specific Diagnosed Prevalent Cases of Epidermolysis Bullosa (EB) in the 7MM) scenario of Epidermolysis Bullosa (EB) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total diagnosed cases of Epidermolysis Bullosa (EB) were found out to be 39,433 in 2017, in the 7MM. The number of Epidermolysis Bullosa (EB) cases in the 7MM is expected to increase during the study period of 2017-2028.

In 2017, there were 26,104 prevalent cases of Epidermolysis Bullosa in the United States. Assessments as per DelveInsight's analysts show that the total prevalent cases of Epidermolysis Bullosa are subjected to increase during the study period.

Among the European countries, the United Kingdom had the highest prevalent population of Epidermolysis Bullosa with 5,037 cases, followed by Germany which had a prevalent population of 4,919 in 2017. On the other hand, Spain had the lowest prevalent population of 928 in 2017.

Epidermolysis Bullosa is of several types, and three major types of Epidermolysis bullosa includes Epidermolysis bullosa simplex (EBS), junctional EB (JEB), and dystrophic EB (DEB). Assessments as per DelveInsight's analysts show that the majority of cases of EB are Epidermolysis bullosa simplex in the United States, however the similar trend is not followed by other countries. In 2017, there were 18,599 cases of EBS, 1,240 cases of JEB, and 4,960 cases of DEB in the United States. DEB is further divided as recessive and dominant. Out of 4,960 cases of DEB in the United States in 2017, 2,358 cases were recessive DEB and 2,602 cases were dominant DEB.

Epidermolysis Bullosa (EB) Report Insights

  • The report covers a descriptive overview of the Epidermolysis Bullosa (EB), explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Epidermolysis Bullosa (EB) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Epidermolysis Bullosa (EB) Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation by Total diagnosed cases
  • Type-specific diagnosed prevalent cases

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by Severity

Table of Contents

1. Key Insights

2. Epidermolysis Bullosa (EB) Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Epidermolysis Bullosa (EB) in 2017
  • 2.2. Patient Share (%) Distribution of Epidermolysis Bullosa (EB) in 2028

3. Epidermolysis Bullosa (EB): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Causes of Epidermolysis Bullosa
  • 3.3. Signs and Symptoms of Epidermolysis Bullosa
  • 3.4. Classification of Epidermolysis Bullosa
  • 3.5. Pathophysiology of Epidermolysis Bullosa
  • 3.6. Genetic Bases of Epidermolysis Bullosa
  • 3.7. Diagnosis of Epidermolysis Bullosa
  • 3.8. Diagnostic Guidelines

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Prevalent Patient Population of Epidermolysis Bullosa
  • 4.3. 7MM Diagnosed Prevalent Patient Population of Epidermolysis Bullosa
  • 4.4. 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa

5. Country Wise-Epidemiology of Epidermolysis Bullosa

  • 5.1. United States Epidemiology
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Prevalent Cases of Epidermolysis Bullosa in the United States
    • 5.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United States
    • 5.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States
  • 5.2. EU5 Epidemiology
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Prevalent Cases of Epidermolysis Bullosa in Germany
      • 5.2.1.3. Diagnosed Prevalence of Epidermolysis Bullosa in Germany
      • 5.2.1.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Prevalent Cases of Epidermolysis Bullosa in France
      • 5.2.2.3. Diagnosed Prevalence of Epidermolysis Bullosa in France
      • 5.2.2.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Italy
      • 5.2.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Italy
      • 5.2.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Prevalent Cases of Epidermolysis Bullosa in Spain
      • 5.2.4.3. Diagnosed Prevalence of Epidermolysis Bullosa in Spain
      • 5.2.4.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom
      • 5.2.5.3. Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
      • 5.2.5.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom
  • 5.3. Japan Epidemiology
    • 5.3.1. Assumptions and Rationale
    • 5.3.2. Total Prevalent Cases of Epidermolysis Bullosa in Japan
    • 5.3.3. Diagnosed Prevalence of Epidermolysis Bullosa in Japan
    • 5.3.4. Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan

6. Appendix

  • 6.1. Report Methodology

7. DelveInsight Capabilities

8. Disclaimer

9. About DelveInsight

List of Tables

  • Table 1 Classification of Epidermolysis Bullosa (EB)
  • Table 2 Level of Evidence
  • Table 3 Grades of recommendation made by the guideline panel
  • Table 4 Level of Evidence
  • Table 5 Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2017-2028)
  • Table 6 Diagnosed Prevalent Patient Population of Epidermolysis Bullosa in the 7MM (2017-2028)
  • Table 7 7MM Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa (2017-2028)
  • Table 8 Total Prevalent Population of Epidermolysis Bullosa in the United States (2017-2028)
  • Table 9 Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
  • Table 10 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
  • Table 11 Total Prevalent Population of Epidermolysis Bullosa in Germany (2017-2028)
  • Table 12 Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
  • Table 13 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
  • Table 14 Total Prevalent Population of Epidermolysis Bullosa in France (2017-2028)
  • Table 15 Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
  • Table 16 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
  • Table 17 Total Prevalent Population of Epidermolysis Bullosa in Italy (2017-2028)
  • Table 18 Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
  • Table 19 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
  • Table 20 Total Prevalent Population of Epidermolysis Bullosa in Spain (2017-2028)
  • Table 21 Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
  • Table 22 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
  • Table 23 Total Prevalent Population of Epidermolysis Bullosa in the United Kingdom (2017-2028)
  • Table 24 Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
  • Table 25 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
  • Table 26 Total Prevalent Population of Epidermolysis Bullosa in Japan (2017-2028)
  • Table 27 Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
  • Table 28 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)

List of Figures

  • Figure 1 Blister formation in Epidermolysis bullosa
  • Figure 2 Some common symptoms of Epidermolysis Bullosa
  • Figure 3 Types of Epidermolysis Bullosa
  • Figure 4 Keratin Proteins and EB Simplex
  • Figure 5 Pathology Outlines
  • Figure 6 The mechanism of epidermolysis bullosa
  • Figure 7 Pathogenesis of Epidermolysis Bullosa Acquisita
  • Figure 8 Total Prevalent Patient Population of Epidermolysis Bullosa in 7MM (2017-2028)
  • Figure 9 Diagnosed Prevalence of Epidermolysis Bullosa in the 7MM (2017-2028)
  • Figure 10 7MM Type Specific Diagnosed Prevalence of Epidermolysis Bullosa (2017-2028)
  • Figure 11 Total Prevalent Cases of Epidermolysis Bullosa in the United States (2017-2028)
  • Figure 12 Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
  • Figure 13 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United States (2017-2028)
  • Figure 14 Total Prevalent Cases of Epidermolysis Bullosa in Germany (2017-2028)
  • Figure 15 Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
  • Figure 16 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Germany (2017-2028)
  • Figure 17 Total Prevalent Cases of Epidermolysis Bullosa in France (2017-2028)
  • Figure 18 Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
  • Figure 19 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in France (2017-2028)
  • Figure 20 Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
  • Figure 21 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Italy (2017-2028)
  • Figure 22 Total Prevalent Cases of Epidermolysis Bullosa in Spain (2017-2028)
  • Figure 23 Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
  • Figure 24 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in Spain (2017-2028)
  • Figure 25 Total Prevalent Cases of Epidermolysis Bullosa in the United Kingdom (2017-2028)
  • Figure 26 Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
  • Figure 27 Type Specific Diagnosed Prevalence of Epidermolysis Bullosa in the United Kingdom (2017-2028)
  • Figure 28 Total Prevalent Cases of Epidermolysis Bullosa in Japan (2017-2028)
  • Figure 29 Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
  • Figure 30 Type-Specific Diagnosed Prevalence of Epidermolysis Bullosa in Japan (2017-2028)
Back to Top